ClinicalTrials.gg
CompletedNCT02757144Updated Apr 25, 2017

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Male Volunteers

A Phase 1 interventional study of DWP14012 and Placebo in Healthy, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-25.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
Male
01

Study summary

This is a dose block-randomized, double-blind, placebo- and active-controlled, single and multiple dosing, dose-escalation clinical phase 1 trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of DWP14012 after oral administration in healthy male volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult males aged between 19 and 50 at screening
  • Those whose weight is between 55 and 90 kg and is between 18.0 and 27.0
  • Those who are adequate to be subjects in this study upon judgment of the investigator after physical examination, clinical laboratory test, examination by interview, etc

Exclusion criteria

Exclusion Criteria:

  • Those who have clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history
  • Those who have gastrointestinal diseases or past history of gastrointestinal diseases (gastrointestinal ulcer, gastritis, gastrospasm, gastroesophageal reflux, Crohn's disease etc.) that may affect safety and pharmacokinetic/pharmacodynamic evaluation of study drug, and those who have past history of gastrointestinal surgery (however, except simple appendectomy and herniotomy)
  • Those who have been Helicobacter pylori positive
  • Those whose plasma (SGOT) and ALT (SGPT) exceed 1.5 times to the in screening including additional examinations prior to randomization
  • Those who have anatomical disability in insertion and maintenance of pH meter catheter
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Cohort 1: DWP14012 Amg

    DWP14012 Amg, tablets, orally, single dose administration

    Drug: DWP14012 · Drug: Placebo

  • Experimental
    Cohort 2: DWP14012 Bmg

    DWP14012 Bmg, tablets, orally, single dose administration

    Drug: DWP14012 · Drug: Placebo

  • Experimental
    Cohort 3: DWP14012 Cmg

    DWP14012 Cmg, tablets, orally, single dose administration

    Drug: DWP14012 · Drug: Placebo

  • Experimental
    Cohort 4: DWP14012 Dmg

    DWP14012 Dmg, tablets, orally, single dose administration

    Drug: DWP14012 · Drug: Placebo

  • Experimental
    Cohort 5: DWP14012 Emg

    DWP14012 Emg, tablets, orally, single dose administration

    Drug: DWP14012 · Drug: Placebo

  • Experimental
    Cohort 6: DWP14012 Fmg

    DWP14012 Emg, tablets, orally, single dose administration

    Drug: DWP14012 · Drug: Placebo

  • Placebo comparator
    Cohort 1-6: Placebo

    DWP14012 placebo-matching tablets, Active-control placebo-matching tablets, orally, single dose administration

    Drug: Placebo

  • Active comparator
    Cohort 1-6: Esomeprazole

    Nexium® tablets, orally, single dose administration

    Drug: Placebo · Drug: Esomeprazole

  • Experimental
    Cohort 7: DWP14012 Amg

    DWP14012 Amg, tablets, orally, repeated dose administration(for 7days)

    Drug: DWP14012 · Drug: Placebo

  • Experimental
    Cohort 8: DWP14012 Bmg

    DWP14012 Bmg, tablets, orally, repeated dose administration(for 7days)

    Drug: DWP14012 · Drug: Placebo

  • Experimental
    Cohort 9: DWP14012 Cmg

    DWP14012 Cmg, tablets, orally, repeated dose administration(for 7days)

    Drug: DWP14012 · Drug: Placebo

  • Placebo comparator
    Cohort 7-10: Placebo

    DWP14012 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 7days)

    Drug: Placebo

  • Active comparator
    Cohort 7-10: Esomeprazole

    Nexium®, orally, repeated dose administration(for 7days)

    Drug: Placebo · Drug: Esomeprazole

  • Experimental
    Cohort 9: DWP14012 Dmg

    DWP14012 Dmg, tablets, orally, repeated dose administration(for 7days)

    Drug: DWP14012 · Drug: Placebo

Interventions

  • DWP14012 tablets

  • DrugPlacebo

    DWP14012 placebo-matching tablets, Active control placebo-matching tablets

  • Nexium®

06

What researchers measure

Primary outcomes

  1. Number and percentage of Participants With Adverse Events (AE)

    All AE standardized using MedDRA was assessed by investigator using the protocol defined grading system. Intensity was categorized as mild, moderate adn severe.

    Time frame: Day -2(Randomization) to Day 11~18(Post-study visit)

  2. Number and percentage of Participants With Adverse Drug Reactions (ADR)

    An adverse drug reaction (ADR) is an injury caused by taking an investigational product.

    Time frame: Day -2(Randomization) to Day 11~18(Post-study visit)

  3. Number of Participants With Clinically Significant Vital Sign findings

    Blood pressure, pulse and body temperature were tested. The Average, Median, Standard Deviation, Min, Max values will be calculated to assess the safety/tolerability.

    Time frame: Day -2(Randomization) to Day 11~18(Post-study visit)

  4. Number of Participants With Clinically Significant Electrocardiogram(12-lead ECG) findings

    Ventricular rate, RR interval, PR interval, QRS duration, QTcB and QTcF were recorded. The results of 12-lead ECG will be categorized Normal/Abnormal NCS(No clinically significant)/Abnormal CS(clinically significant).

    Time frame: Day -2(Randomization) to Day 11~18(Post-study visit)

  5. Number of Participants With Clinically Significant Laboratory results

    Hematology, Blood chemistry, Coagulation and Urinalysis were tested. The Average, Median, Standard Deviation, Min, Max values will be calculated to assess the safety/tolerability.

    Time frame: Day -2(Randomization) to Day 11~18(Post-study visit)

Secondary outcomes

  1. Cmax: Maximum concentration of DWP14012

    in single ascending dose cohort

    Time frame: 0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours

  2. Cmax,ss: Maximum concentration of DWP14012 at steady state

    in multiple ascending dose cohort

    Time frame: 0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24h, Day 3-6 pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours

  3. Cmin,ss: Minimum concentration of DWP14012 at steady state

    in multiple ascending dose cohort

    Time frame: 0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24h, Day 3-6 pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours

  4. Tmax: Time of maximum concentration

    in single ascending dose cohort

    Time frame: 0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours

  5. Tmax,ss: Time of maximum concentration at steady state

    in multiple ascending dose cohort

    Time frame: 0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24h, Day 3-6 pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours

  6. AUClast: Area under the plasma concentration-time curve from time 0 to 48hours

    in single ascending dose cohort

    Time frame: 0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours

  7. AUCinf: Area under the plasma concentration-time curve from time 0 to infinity

    in single ascending dose cohort

    Time frame: 0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours

  8. AUCtau: Area under the plasma concentration-time curve from time 0 to tau(dosing interval)

    in multiple ascending dose cohort

    Time frame: 0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24h, Day 3-6 pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours

  9. T1/2: Elimination half-life

    in single ascending dose cohort

    Time frame: 0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours

  10. T1/2: Elimination half-life

    in multiple ascending dose cohort

    Time frame: 0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24h, Day 3-6 pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours

  11. Percentage of total time that the intragastric pH was above 4

    After single administration of the investigational products, 24hr gastric pH monitoring started.

    Time frame: Day 1

  12. Percentage of total time that the intragastric pH was above 4

    After multiple administration of the investigational products, 24hr gastric pH monitoring started.

    Time frame: Day 7

  13. Serum gastrin concentration profile

    Time frame: Day -2(Randomization) to Day 11~18(Post-study visit)

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2016 to primary completion in Feb 2017, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2016
First posted
Apr 29, 2016
StartActual
Mar 2016
Primary completionActual
Feb 2017
CompletionActual
Feb 2017
Last update
Apr 25, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02757144
Responsible party
Sponsor
First posted
Apr 29, 2016
Start date
Mar 2016
Primary completion
Feb 2017
Completion
Feb 2017
Last update
Apr 25, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexuprazan

Start the discussion